Pelthos Therapeutics has secured the rights to market non-fluorinated quinolone antimicrobial, Xepi (ozenoxacin) cream, 1% in ...

Acquisition adds complementary dermatology product to the Pelthos portfolio anchored by ZELSUVMI™Xepi is a novel FDA-approved ...

Background.Scabies is a public health problem in many countries, with impetigo and its complications important consequences. Ivermectin based mass drug administration (MDA) reduces the prevalence of ...

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology ...

Rash during pregnancy is not uncommon, ranging from a relatively harmless heat rash to potentially life-threatening conditions like impetigo herpetiformis. These rashes may develop due to changes in ...

Biopharma company Pelthos Therapeutics has acquired the US commercialization rights to Xepi (ozenoxacin) Cream, 1%, from ...

A Durham drugmaker has added another product to its portfolio with a recent acquisition.